What were the key takeaways from Teva Pharmaceutical's earnings call?

What does Teva Pharmaceutical do and what are its main business segments?

What were the key takeaways from Teva Pharmaceutical’s earnings call?

What guidance did Teva Pharmaceutical's management provide for the next earnings period?

Did Teva Pharmaceutical beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Teva Pharmaceutical next quarter?

What is Teva Pharmaceutical's gross profit margin?

What is Teva Pharmaceutical's latest dividend and current dividend yield?

- **Innovative Portfolio Dominance**: AUSTEDO, UZEDY, and AJOVY drove 35% YoY growth, with AUSTEDO on track for $2.4-$2.55 billion in 2026.
- **Pipeline Acceleration**: 7 key milestones in 2026, including duvakitug maintenance data, olanzapine LAI approval, and anti-IL-15 vitiligo results.
- **Financial Strength**: 2025 free cash flow of $1.9 billion, with 2026 guidance of $2-$2.4 billion, supported by 6% CAGR and 30% operating margin target.
- **Biosimilars Expansion**: 10 launched biosimilars, 6 more by 2027, and 10+ pipeline assets targeting $10 billion peak sales.

**【CEO Summary Section】**
- **Revenue Growth and Financial Highlights**: Q4 2025 revenue of $17.3 billion (+5% YoY), EBITDA of $5.3 billion (+12% YoY), EPS of $2.93 (+19% YoY), and free cash flow of $2.4 billion (+16% YoY). The company is on track to achieve 2x net debt-to-EBITDA ratio by 2027.
- **Innovative Portfolio Momentum**: AUSTEDO, UZEDY, and AJOVY combined revenue reached $3.1 billion (+35% YoY). AUSTEDO grew 34% to $2.26 billion, UZEDY 63% to $191 million, and AJOVY 30% to $673 million. Q4 2025 guidance for AUSTEDO is $2.4-$2.55 billion, UZEDY $250-$280 million, and AJOVY $750-$790 million.
- **Pipeline Progress**: Phase III studies for olanzapine LAI (schizophrenia), duvakitug (UC/CD), and DARI (asthma) are advancing. Anti-IL-15 program for vitiligo and celiac disease is supported by Royalty Pharma funding.
- **Biosimilars Expansion**: 10 biosimilars launched globally, with 6 more planned by 2027. The portfolio includes biosimilars for Prolia, Xgeva, Simponi, Eylea, and Xolair.

**【CFO Financial Commentary】**
- **2025 Financial Performance**: Full-year revenue $17.3 billion, non-GAAP EPS $0.68, and free cash flow $1.9 billion. Gross margin improved to 54.7%, driven by innovative product growth.
- **2026 Guidance**: Revenue $16.4-$16.8 billion, non-GAAP EPS $2.57-$2.77, and free cash flow $2-$2.4 billion. Operating expenses expected to be 27%-28% of revenue, with savings from $700 million transformation program.
- **Key Risks**: $1.1 billion headwind from generic Revlimid in 2026, and potential AUSTEDO destocking ahead of IRA implementation in 2027.

**【Q&A Highlights】**
- **AUSTEDO Pricing Dynamics**: Management expects stable net pricing, with 2026 guidance reflecting 11%-18% growth excluding one-time Q4 2025 benefits.
- **UZEDY Medicaid Exposure**: Guidance accounts for Medicaid mix, with TRx growth driven by new patient transitions.
- **Pipeline Milestones**: Duvakitug maintenance data (Q1 2026), olanzapine LAI approval (Q4 2026), and anti-IL-15 vitiligo Phase IIb results (Q1 2026).
- **Biosimilar Strategy**: Partnerships (e.g., mAbxience, Samsung) will drive U.S. and European biosimilar launches, targeting 10 new assets by 2028.

Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: 3% Q3 growth, 33% innovative portfolio expansion (AUSTEDO +38%, UZEDY +24%). 
- **Margin & Debt**: 28.9% operating margin, net debt-to-EBITDA 2.8x (target 2x by 2027). 
- **Strategic Wins**: 11th straight quarter of growth; $2.5 billion AUSTEDO 2027 target reaffirmed. 
- **Pipeline Momentum**: Olanzapine LAI FDA submission Q4 2025; duvakitug Phase III underway. 
- **Cost Efficiency**: $700M savings program 50% achieved in 2025, driving 2027 margin goals.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue reached $4.5 billion, up 3% year-over-year, driven by 33% growth in the innovative portfolio (AUSTEDO, UZEDY, AJOVY). AUSTEDO revenue surged 38% to $618 million, UZEDY grew 24%, and AJOVY rose 19%. 
- **Strategic Milestones**: 11th consecutive quarter of revenue growth; 2027 targets include mid-single-digit growth, 30% operating margin, and $2.5 billion AUSTEDO revenue. 
- **Pipeline Progress**: Olanzapine LAI FDA submission planned for Q4 2025; DARI and duvakitug Phase III studies on track. 
- **Cost Optimization**: $700 million cost savings program on track, with $70 million achieved in 2025. Net debt-to-EBITDA ratio dropped to 2.8x, below 3x for the first time since 2016.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income $433 million, non-GAAP EPS $0.78 (up 14% YoY). Free cash flow $515 million. 
- **Margin Expansion**: Non-GAAP gross margin 55.3% (up 120bps YoY), operating margin 28.9% (up 70bps YoY). 
- **2025 Outlook**: Tightened revenue guidance to $16.8–$17 billion; AUSTEDO updated to $2.05–$2.15 billion. 2027 targets reaffirmed: $2.5 billion AUSTEDO, 30% operating margin, 2x net debt-to-EBITDA.

**【Q&A Highlights】**
- **AUSTEDO IRA Negotiations**: CMS agreement aligns with 2023 forecasts, supporting $2.5 billion 2027 target. AUSTEDO XR included in negotiations. 
- **Competitive Dynamics**: Emphasized underserved TD market (85% untreated patients). Biosimilar pipeline expansion and TAPI sale process restart noted. 
- **Pipeline Updates**: Olanzapine LAI Phase III data positive; duvakitug Phase III IBD studies initiated. 
- **Free Cash Flow**: 2027 free cash flow inflection driven by innovative growth, cost savings, and debt reduction.

Teva Pharmaceutical Industries Limited (TEVA) Q3 2025 Earnings Call Transcript

- **Innovative Growth**: Q2 revenue up 1% YoY, driven by AUSTEDO (+19%), UZEDY (+120%), and AJOVY (+31%). 2025 guidance raised for all three products.
- **Margin Expansion**: Non-GAAP gross margin 54.6% (up 130bps YoY), with free cash flow at $476 million.
- **Cost Savings**: $700 million net savings program on track, with 20% of 2/3 target achieved.
- **Biosimilar Pipeline**: 8 biosimilars launching by 2027, targeting $800 million in 2027.
- **Tariff Resilience**: >50% U.S. products domestically manufactured; no immediate financial impact.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue of $4.2 billion, up 1% YoY, driven by innovative portfolio (AUSTEDO +19%, UZEDY +120%, AJOVY +31%).
- **Innovative Portfolio Expansion**: Raised 2025 guidance for AUSTEDO to $2 billion, UZEDY to $190-200 million, and AJOVY to $640 million. Olanzapine LAI expected to launch in 2026 with peak sales potential of $1.5-2 billion.
- **Generics Performance**: Global generics down 2% YoY due to tough comparables, but stable with 15 complex generics and 8 biosimilars launching by 2027.
- **Teva Transformation**: On track to deliver $700 million net savings by 2027, with 20% of 2/3 target achieved.

**【CFO Financial Commentary】**
- **Financial Highlights**: Non-GAAP EPS of $0.66 (+10% YoY), free cash flow $476 million (+47% YoY), and net debt/EBITDA of 3.0x.
- **Gross Margin Expansion**: 54.6% (up 130bps YoY) driven by portfolio mix shift to high-margin innovatives.
- **Balance Sheet Strength**: $17.2 billion gross debt post-refinancing, with credit rating upgrades.
- **Tariff Mitigation**: >50% of U.S. products manufactured domestically; no immediate impact expected.

**【Q&A Key Highlights】**
- **AUSTEDO XR Adoption**: 60%+ new patients on XR, targeting majority of patients long-term.
- **Biosimilar Momentum**: SELARSDI launch in Q1 2025, with 5 additional U.S. biosimilars by end-2025.
- **Tariff Strategy**: Flexible supply chain and U.S. manufacturing mitigate risks; no material impact anticipated.
- **2027 Targets**: Confident in $3.5-4 billion innovative revenue, 30% operating margin, and $800 million biosimilar sales.

Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript

- **Record Growth**: 9th straight quarter of revenue expansion, driven by 45% jump in innovative drugs.
- **Margin Ambition**: 30% operating margin by 2027 via $700M savings, offsetting $1B Revlimid cliff.
- **Pipeline Momentum**: Olanzapine LAI launch Q2 2025, duvakitug Phase 3 starts H2 2025.
- **Resilience**: Tariff impact neutralized, U.S. manufacturing base protects supply chain.

**【CEO Summary Section】**
- Ninth consecutive quarter of growth with Q1 2025 revenue of $3.9 billion (5% YoY in local currency). 
- Innovative brands drove 45% YoY growth: Austedo (+39%), Ajovy (+26%), Uzedy (+100%).
- Biosimilar launches (Humira, Soliris) and TAPI discussions advancing.
- 2027 targets: $2.5B Austedo sales, 30% operating margin, $700M net savings.

**【CFO Financial Commentary】**
- Q1 2025: Non-GAAP EPS $0.52 (+8%), Adjusted EBITDA $1.1B, Free Cash Flow $320M.
- Gross margin 52.8% (+140bps YoY) driven by Austedo mix.
- 2025 guidance: Revenue $16.8-17.2B, EPS $2.45-2.65 (up $0.10 low end).
- 2026-2027: 400bps margin expansion via $700M savings, offsetting Revlimid cliff.

**【Q&A Highlights】**
- Generics remain 'sustainable powerhouse' but biosimilars to drive faster growth.
- Tariffs absorbed in 2025 guidance; U.S. manufacturing mitigates risk.
- Olanzapine LAI NDA submission Q2 2025, Phase 3 for duvakitug starting H2 2025.
- 2026 EBITDA growth expected despite Revlimid headwinds.

Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call Transcript

- **Revenue Growth**: 9% YoY to $16.5B, driven by AUSTEDO (+34%), UZEDY ($117M), and generics (11% growth).
- **Pipeline Breakthroughs**: Duvakitug Phase 3 data shows best-in-class efficacy; olanzapine NDA in 2025.
- **Financial Strength**: Free cash flow $2.1B, net debt/EBITDA 3x (target 2x by 2027). 2025 guidance: $16.8-17.4B revenue, 30% EBITDA target by 2027.
- **Strategic Moves**: 7 US biosimilars launches, 6%+ R&D investment, and $500M Sanofi partnership.

**【CEO Summary Section】**
- **Pivot to Growth Strategy Progress**: Achieved 9% revenue growth in 2024, driven by innovative products (AUSTEDO +34%, UZEDY +117M, AJOVY +18%) and generics (11% growth). 2027 target: 5% CAGR.
- **Pipeline Momentum**: Duvakitug Phase 3 data shows best-in-class efficacy; olanzapine NDA submission expected in 2025. Biosimilars to launch 7 in US and 4 in Europe by 2026.
- **Capital Allocation**: Prioritizes R&D (6%+ of revenue) and debt reduction (net debt/EBITDA ~3x, target 2x by 2027).

**【CFO Financial Commentary】**
- **2024 Results**: Revenue $16.5B (+8%), EBITDA $4.8B (+9%), free cash flow $2.1B. Non-GAAP EPS $2.49 (+10%).
- **2025 Guidance**: Revenue $16.8-17.4B (+2-5%), gross margin 53-54%, EBITDA $4.1-4.6B. Free cash flow $1.6-1.9B.
- **Financial Health**: Net debt $14.5B, credit ratings upgraded. Focus on FX hedging and cost optimization.

**【Q&A Key Highlights】**
- **EBITDA Trajectory**: 2025 margin compression due to R&D/S&M investments, but 2027 target 30% remains intact via portfolio mix shift.
- **Revlimid Mitigation**: 16 complex generics launches and biosimilars to offset 2026 cliff; AUSTEDO growth to 2027+.
- **TL1A Partnership**: Sanofi cost-sharing for Phase 3; duvakitug potential in IBD, idiopathic pulmonary fibrosis.
- **Litigation Risk**: CMS lawsuit timing uncertain; focus on 2025 biosimilar launches.

Teva Pharmaceutical Industries Limited (TEVA) Q4 2024 Earnings Conference Call Transcript

Teva Pharmaceutical Industries Limited (TEVA) Q2 2024 Earnings Call Transcript

Teva Pharmaceutical Industries Limited (TEVA) Q1 2024 Earnings Call Transcript

Actual											0.76	0.55	0.58	0.68	0.63	0.59	0.59	0.77	0.55	0.68	0.59	0.71	0.4	0.56	0.6	1	0.48	0.61	0.69	0.71	0.52	0.66	0.78	0.96
Forecast											0.5917	0.5257	0.5821	0.6283	0.5908	0.5923	0.6446	0.7338	0.5491	0.5814	0.6159	0.715	0.557	0.5252	0.6078	0.7675	0.5138	0.552	0.6613	0.7073	0.4625	0.6167	0.6901	0.6413
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+28.44%	+4.62%	-0.36%	+8.23%	+6.64%	-0.39%	-8.47%	+4.93%	+0.16%	+16.96%	-4.21%	-0.70%	-28.19%	+6.63%	-1.28%	+30.29%	-6.58%	+10.51%	+4.34%	+0.38%	+12.43%	+7.02%	+13.03%	+49.70%

TEVA

TEVA fundamentals

TEVA Q4 2025 Earnings

Earnings Call

You can ask Aime

TEVA

TEVA fundamentals

TEVA Q4 2025 Earnings

Earnings Call

TEVA Earnings Call Summary for Q4/20258:00 AM on Jan 28, 2026

TEVA Earnings Call Summary for Q3/20258:00 AM on Nov 5, 2025

TEVA Earnings Call Summary for Q2/20258:00 AM on Jul 30, 2025

TEVA Earnings Call Summary for Q1/20258:00 AM on May 7, 2025

TEVA Earnings Call Summary for Q4/20248:00 AM on Jan 29, 2025

You can ask Aime